What the business is
Eli Lilly is a US pharmaceutical group whose injectable weight-loss drugs Mounjaro and Zepbound drove 48% revenue growth last quarter.
The bet
Selling Mounjaro direct through its own online platform lets Lilly reach patients without a subsidy deal and without losing them to price shopping.
How it started
After protracted negotiations with the federal government, Lilly said in April it would not proceed with the Pharmaceutical Benefits Scheme listing process, citing among other grievances that the price Australia would pay was too low.
What happened
LillyDirect, which launched in the US in 2024, went live in Australia the week before the 30 September report. Lilly's Australian site advertises two telehealth providers, including Juniper. The Royal Australian College of GPs, the Pharmacy Guild and the Pharmaceutical Society of Australia criticised the model as clinically inferior and a patient-safety risk; Lilly said a registered Australian pharmacist reviews and dispenses every script and that doctors still prescribe.
What has to be true
Lilly walked away from PBS listing over the price Australia offered, so it needed another route to patients
Mounjaro demand had exploded, and Lilly's revenue grew 48% last quarter on Mounjaro and Zepbound
LillyDirect already operated in the US since 2024, so the model was ready to export
A direct platform lets Lilly list partner telehealth providers and a price without a pharmacy middleman
What can be applied
A manufacturer that goes direct to patients to sidestep a price negotiation takes on the regulatory and trust fights its distributors used to absorb.
Aftermath
As of 30 September 2026 the platform was live and drawing condemnation from GP, pharmacist and academic voices, while Lilly defended it as operating within existing Australian regulatory frameworks. No regulatory action against it was reported in the article.
FOLLOW THE EVIDENCE